Troponin T measurements by high-sensitivity vs conventional assays for risk stratification in acute dyspnea

Clinical Chemistry

Volumn 58, Issue 1, 2012, Pages 284-292

  Van Wijk, Sandra ^a   Jacobs, Leo ^a   Eurlings, Luc W ^a   Van Kimmenade, Roland ^a   Lemmers, Roosmarijn ^a   Broos, Pieter ^a   Bekers, Otto ^a   Prins, Martin H ^a   Crijns, Harry J ^a   Pinto, Yigal M ^b   Van Dieijen Visser, Marja P ^a   Brunner La Rocca, Hans Peter ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; TROPONIN T;

ACUTE DISEASE; AGED; ARTICLE; BIOASSAY; CONTROLLED STUDY; DYSPNEA; EMERGENCY WARD; FEMALE; HAZARD RATIO; HUMAN; LIMIT OF DETECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATIENT IDENTIFICATION; PROGNOSIS; PROSPECTIVE STUDY; RISK; RISK ASSESSMENT; STRATIFICATION; STRATIFIED SAMPLE;

ACUTE DISEASE; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; DYSPNEA; HUMANS; PROGNOSIS; PROSPECTIVE STUDIES; REFERENCE VALUES; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TROPONIN T;

EID: 84856076156     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2011.175976     Document Type: Article

References (30)

1. Morrow DA, Cannon CP, Jesse RL, Newby LK, Ravkilde J, Storrow AB, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Circulation 2007;115:e356-75. (Pubitemid 46648624)
2. Thygesen K, Alpert JS, White HD, Jaffe AS, Apple FS, Galvani M, et al. Universal definition of myocardial infarction. Circulation 2007;116:2634-53. (Pubitemid 350182388)
3. Hamm CW, Giannitsis E, Katus HA. Cardiac troponin elevations in patients without acute coronary syndrome. Circulation 2002;106:2871-2. (Pubitemid 35424732)
4. Kelley WE, Januzzi JL, Christenson RH. Increases of cardiac troponin in conditions other than acute coronary syndrome and heart failure. Clin Chem 2009;55:2098-112.
5. Peacock WFt, De Marco T, Fonarow GC, Diercks D, Wynne J, Apple FS, Wu AH. Cardiac troponin and outcome in acute heart failure. N Engl J Med 2008;358:2117-26.
6. Perna ER, Macin SM, Canella JP, Augier N, Stival JL, Cialzeta JR, et al. Ongoing myocardial injury in stable severe heart failure: value of cardiac troponin T monitoring for high-risk patient identification. Circulation 2004;110:2376-82. (Pubitemid 39407342)
7. Khan NA, Hemmelgarn BR, Tonelli M, Thompson CR, Levin A. Prognostic value of troponin T and I among asymptomatic patients with end-stage renal disease: a meta-analysis. Circulation 2005;112:3088-96. (Pubitemid 43113440)
8. Sommerer C, Beimler J, Schwenger V, Heckele N, Katus HA, Giannitsis E, Zeier M. Cardiac biomarkers and survival in haemodialysis patients. Eur J Clin Invest 2007;37:350-6. (Pubitemid 46653136)
9. van den Bos EJ, Constantinescu AA, van Domburg RT, Akin S, Jordaens LJ, Kofflard MJ. Minor elevations in troponin I are associated with mortality and adverse cardiac events in patients with atrial fibrillation. Eur Heart J 2011;32:611-7.
10. Lankeit M, Friesen D, Aschoff J, Dellas C, Hasenfuss G, Katus H, et al. Highly sensitive troponin T assay in normotensive patients with acute pulmonary embolism. Eur Heart J 2010;31:1836-44.
11. Giannitsis E, Kurz K, Hallermayer K, Jarausch J, Jaffe AS, Katus HA. Analytical validation of a high-sensitivity cardiac troponin T assay. Clin Chem 2010;56:254-61.
12. Wu AH. Biochemical markers of cardiac damage: from traditional enzymes to cardiac-specific proteins. IFCC Subcommittee on Standardization of Cardiac Markers (S-SCM). Scand J Clin Lab Invest 1999;230:74-82. (Pubitemid 29279359)
13. Latini R, Masson S, Anand IS, Missov E, Carlson M, Vago T, et al. Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure. Circulation 2007;116:1242-9. (Pubitemid 47517535)
14. Omland T, de Lemos JA, Sabatine MS, Christophi CA, Rice MM, Jablonski KA, et al. A sensitive cardiac troponin T assay in stable coronary artery disease. N Engl J Med 2009;361:2538-47.
15. Meune C, Drexler B, Haaf P, Reichlin T, Reiter M, Meissner J, et al. The Grace score's performance in predicting in-hospital and 1-year outcome in the era of high-sensitivity cardiac troponin assays and B-type natriuretic peptide. Heart (British Cardiac Society) 2011.
16. Reichlin T, Hochholzer W, Bassetti S, Steuer S, Stelzig C, Hartwiger S, et al. Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. N Engl J Med 2009;361:858-67.
17. Manning HL, Schwartzstein RM. Pathophysiology of dyspnea. N Engl J Med 1995;333:1547-53.
18. Michelson E, Hollrah S. Evaluation of the patient with shortness of breath: an evidence based approach. Emerg Med Clin North Am 1999;17:221-37, x. (Pubitemid 29147014)
19. Christ M, Thuerlimann A, Laule K, Klima T, Hochholzer W, Perruchoud AP, Mueller C. Long-term prognostic value of B-type natriuretic peptide in cardiac and non-cardiac causes of acute dyspnoea. Eur J Clin Invest 2007;37:834-41. (Pubitemid 350029207)
20. Gegenhuber A, Mueller T, Dieplinger B, Poelz W, Pacher R, Haltmayer M. B-type natriuretic peptide and amino terminal proBNP predict one-year mortality in short of breath patients independently of the baseline diagnosis of acute destabilized heart failure. Clin Chim Acta 2006;370:174-9. (Pubitemid 44137286)
21. Januzzi JL Jr, Sakhuja R, O'Donoghue M, Baggish AL, Anwaruddin S, Chae CU, et al. Utility of amino-terminal pro-brain natriuretic peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the emergency department. Arch Intern Med 2006;166:315-20. (Pubitemid 43244319)
22. Jacobs LH, van de Kerkhof J, Mingels AM, Kleijnen VW, van der Sande FM, Wodzig WK, et al. Haemodialysis patients longitudinally assessed by highly sensitive cardiac troponin T and commercial cardiac troponin T and cardiac troponin I assays. Ann Clin Biochem 2009;46:283-90.
23. Mingels A, Jacobs L, Michielsen E, Swaanenburg J, Wodzig W, van Dieijen-Visser M. Reference population and marathon runner sera assessed by highly sensitive cardiac troponin T and commercial cardiac troponin T and I assays. Clin Chem 2009;55:101-8.
24. Hlatky MA, Greenland P, Arnett DK, Ballantyne CM, Criqui MH, Elkind MS, et al. Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation 2009;119:2408-16.
25. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008;27:157-72; discussion 207-12.
26. Vergara IA, Norambuena T, Ferrada E, Slater AW, Melo F. Star: a simple tool for the statistical comparison of ROC curves. BMC Bioinforma 2008;9:265.
27. McGill D, Talaulikar G, Potter JM, Koerbin G, Hickman PE. Over time, high-sensitivity TNT replaces NT-proBNP as the most powerful predictor of death in patients with dialysis-dependent chronic renal failure. Clin Chim Acta 2010;411:936-9.
28. deFilippi CR, de Lemos JA, Christenson RH, Gottdiener JS, Kop WJ, Zhan M, Seliger SL. Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults. JAMA 2011;304:2494-502.
29. Otsuka T, Kawada T, Ibuki C, Seino Y. Association between high-sensitivity cardiac troponin T levels and the predicted cardiovascular risk in middleaged men without overt cardiovascular disease. Am Heart J 2010;159:972-8.
30. Jaffe AS. The 10 commandments of troponin, with special reference to high sensitivity assays. Heart (British Cardiac Society) 2011;97:940-6.